Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

The German Industry’s Innovation Award 2010 for PEPperPRINT

No. 10 | 19/02/2011

PEPperPRINT GmbH was announced on February 19, 2011 as the winner of the 2010 German Industry’s Innovation Award in the category “Start-Up Companies”. PEPperPRINT, a start-up company founded by scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), produces peptide microarrays for research and diagnostics using a novel and low-cost technology.
Joint Press Release of the German Cancer Research Center (DKFZ) and Karlsruhe Institute of Technology (KIT)

Dr. Frank Breitling, Dr. Volker Stadler, Thomas Felgenhauer, Dr. Ralf Bischoff (from left to right)
© dkfz.de

Numerous biochemical and medical detection methods are based on the use of short chains of amino acids called peptides which are produced synthetically and affixed on the surface of a piece of glass. Such peptide microarrays can be used for identifying pathogens or developing new substances for drugs. Diagnosis of cancers might also be improved with these microarrays. A disadvantage of peptide microarrays has been that their production is time-consuming and costly.

Dr. Volker Stadler (PEPperPRINT), Dr. Frank Breitling (KIT) and Dr. Ralf Bischoff (DKFZ) are co-founders of PEPperPRINT GmbH. Over the past few years they have developed a novel technique that overcomes the technological hurdles in the production of peptide microarrays. The company’s name, PEPperPRINT, says it all: The twenty different peptide building blocks are embedded in toner particles and printed on the glass surface using a special 24 color laser printer. This production technology makes it possible to increase the number of peptides per surface by 80 times and reduce manufacturing costs by 50 times. The technology therefore opens up a whole new range of options for research.

This concept was also commended by the jurors of the German Industry’s Award 2010. PEPperPRINT was the winner in the category “Start-Up Companies”, i.e. companies that have been competing in the market for less than five years. Last Saturday, PEPperPRINT, which started operations in 2010, was presented the prestigious award, which is also the world’s first innovation award. Since 1980, the Rhine-Main Industry Club (Wirtschaftsclub Rhein-Main) has annually rewarded Germany’s most innovative enterprises with this award.

The 2010 award winners were honored at a festive event at Frankfurt’s Congress Center for their outstanding technological, scientific and intellectual accomplishments by Research Minister Annette Schavan, who sponsors the innovation award. “We are very happy and proud of this distinction!” said Volker Stadler after receiving the award. “Of course, there is a lot more to come. Peptide microarrays will become increasingly important for science and we are continuously working to refine our products for new applications,” said Frank Breitling explaining PEPperPRINT’s business strategy.

In cooperation with the Karlsruhe Institute of Technology (KIT), where Frank Breitling has been working since 2009, production of peptide microarrays will be optimized in the future. Aims include further increasing the number of peptides per microarray while at the same time reducing costs of production – and, thus, of healthcare research. At KIT, one of the leading energy research centers in Europe, projects will also aim to develop peptide microarrays in a modified form towards photovoltaic and fuel cells.

A picture of the PEPperPRINT Team is available on the Internet at:
http://www.dkfz.de/de/presse/pressemitteilungen/2011/images/pepperprint.JPG
Picture caption, from left to right: Dr. Frank Breitling, Dr. Volker Stadler, Thomas Felgenhauer, Dr. Ralf Bischoff
Source: Nicole Schuster, DKFZ

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Cancer Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS